PROFORMA FOR NOMINATIONS For individuals 1. Name of the Nominee: Dr Jaya Shukla 2. Date of Birth: 24.05.1967 3. Present position /designation: Associate Professor 4. Address with Tele/Fax/E-mail:Department of Nuclear Medicine, Post Graduate Institute of Medical Education & Research, Chandigarh India 160012; Tele: 0172-2756724(off), 9781533400 (M), [email protected] 5. Academic qualifications (in the form of a table from Bachelor's degree onwards including particulars such as subject, class/division, names of institutions, year, rank/prizes, etc. Degree Subject Year Division University/Institution B.Sc Zoology, Botany, 1986 II A.N.D. College, Kanpur University Chemistry M.Sc Biochemistry 1989 I G B Pant University, Pant Nagar, Uttaranchal, India Ph.D Radiochemistry Sept - All India Institute of Medical sciences. New Delhi, 2005 India 6.Positions held (In chronological order) Position held Period Name of Institute From To JRF(IAEA project) 14 Dec2000 30Dec2001 All India Institute of Medical Sciences,Delhi Research 4 Mar2006 3Aug2006 AIIMS, Delhi Associate(ICMR Project) Women Scientist Fellow 4Aug 2006 3Feb 2010 AIIMS, Delhi (DST-WOS AProject) Research officer (ICMR) 4 Feb 2010 9 May 2010 AIIMS, Delhi Research officer (DST) 10 May 2010 5 May 2011 AIIMS, Delhi Assistant Professor 6 May 2011 20 June 2014 Post Graduate Institute of Medical Education & Research, Chandigarh Associate Professor 1 July 2014 Till Date PGIMER, Chandigarh 7. Current area of Research (Not more than 200 words): Separate sheet enclosed 8. (a) List of publications in indexed journals: (Separate sheet enclosed) (b) List of reviews 1. Shukla J, Mittal BR. Dimercaptosuccinic acid: A multifunctional cost effective agent for imaging and therapy. Indian J Nucl Med. 2015;30(4):295-302. (c) Overseas Visits (indicate the duration of the visit with dates, name of the institute /laboratory/organization andcountry, purpose etc.) S.N. Duration Place purpose 1 15-18 Mar 11th European Sumposium on Radiopharmacy& Invited paper presentation 2003 Radiopharmaceuticals, Innsbruck, Austria 2 19-23 June Annual Meeting of society of Nuclear Medicine, Scientific Paper 2004 Philadelphia, USA presentation & won „Best basic science Paper- Travel Award 3 4-6 Nov International Meeting of Nuclear Medicine of Scientific Paper 2005 Northern Greece, Thessaloniki presentation& won „First prize‟ 4 8-12 July UICC World Cancer Congress, Washington DC, Scientific Paper 2006 USA presentation 5 13-17 June 56thAnnual Meeting of society of Nuclear Scientific Paper 2009 Medicine, Toranto, Canada presentation 6 28 June-27 Radiopharmaceutical Research and Molecular UICC- ICRETT fellowship July 2010 Imaging lab,ThomasJafferson University, Philadelphia USA 7 24-17 April 17th European Symposium on Radiopharmacy Scientific 2014 and Paper presentation Radiopharmaceuticals(ESRR)Pamplona,Spain 8 10-25 Aug Radiopharmaceutical Research and Molecular Academic Visit 2014 Imaging lab,ThomasJafferson University, Philadelphia USA 27-31 Aug Scientific 2014 XI Congress of the World Federation of Nuclear Paper presentation Medicine (WFNM). Cancun, Maxico 9 5- 2nd Asian Nuclear Medicine Academic forum Selected gor presentation 8May2016 (ANMAF), Shanghai, China from India,„Bronze Award‟ NM Professional Challenge 10 7-10 Sept World Molecular Imaging Congress (WMIC), New Scientific 2016 York, USA Paper presentation 11-25 Sept Radiopharmaceutical Research and Molecular Academic Visit 2016 Imaging lab,ThomasJafferson University, Philadelphia USA (d) Particulars of memberships of academies/scientific societies/professional bodies 1) Fellows- Association of UICC 2) Member –National Academy of Medical Sciences (NAMS) 3) Member -Indian college of Nuclear Medicine (ICNM) 4) Life Member- Society of Nuclear Medicine India (SNMI) 5) Member- Indian Association of Biomedical Scientists (IABMS) 6) Member-World Association of Radiopharmaceutical & Molecular Therapy (WARMTH) 7) Member of Editorial Board- Indian Journal of Nuclear Medicine (IJNM) (e) Awards won (give full particulars such as title, awarding agency / organization, the achievements for which award was conferred etc.) i. Best Paper Award During 11th International Conference on Radiopharmaceutical Therapy Kochi, Kerala, India 13-17 Nov 2016 ii. TiE Trailblazer Award for Innovation during 8th India Innovation Initiative-i3 National Fair 2016 Delhi, 19th Oct 2016 iii. Won “Bronz Medal” in Rising NM Professional ChallengeAwards by Asian School of Nuclear Medicine during 2nd Asian Nuclear Medicine Academic forum (ANMAF), 5-8 May 2016, Shanghai, China. iv. UICC ICRET Fellowship 2010 v. DST Women Scientist Fellowship (WOS-A)2006 vi. „First prize’ at 3rd International Conference Hellenic Society of Nuclear Medicine Thessaloniki, Greece, 2005 vii. Travel Award for the Best Basic Science Paper at 51st Annual meeting of Society of Nuclear Medicine, Philadelphia, USA, 2004. (f)List of Patents taken/applied: Two- PatentNumber- 1) 2084-DEL-2015 2) 2085-DEL-2015 9. Details not exceeding 500 words including (a) Title, Summary & Justification for being awarded ofthe Biotech Product & Process Developed during the past five years in the areas of biosciences/ biotechnology (b) status of its commercialization including the name of the industry to which transferred (c) status of patent obtained/applied and (d) production figures of product and cost realized during last five years for which the nominee is recommended for the award- Separates Sheet enclosed 10.Any other relevant information in support of the nomination: (References and Images related to Product in separate sheet- 11. Aadhar No. : 547837986510 Date :21.1.2017 Place: Chandigarh (Signature of the Nominee) DR JAYA SHUKLA (Name ) Enclosures 7. Current area of Research 1. The development of ready to use Kit for Re-188 preparation in Nuclear Medicine Departments/centres 2. Project entitled “Studies on theranostic application of Ga-68/Lu-177-DOTATrastuzumab in Her2/neu over-expressing breast cancer patients” is expansion of the our previous work. Lu-177- DOTA- Trastuzumab (Herceptin ) is developed as a theranostic device for the metastatic Her2/neu expressing breast cancers. (Patent Application No-2084-DEL-2015);(Int J Cancer. 2016 Nov 3. doi: 10.1002/ijc.30500). Collaborators: BARC, Mumbai; Funded by DAE, BRNS, Govt of India. 3. The project entitled A Preliminary study to compare the uptake of 68Ga-DOTA-TATE PET/CT and 131I-MIBG scintigraphy in patient with neuroendocrine tumors”. MIBG is supplied once a month. 68Ga-DOTANOC PET/CT can be prepared any time due to availability of Ge-68/Ga-68 generator, and provide good image quality for interpretation of disease condition.Funded by ICMR. (JNucl Med 2016, 57; (supplement 2): 1510-1510). 4. Radioactive skin patch (Re-188) therapy for basal cell carcinoma and keloids. colloidal Re-188 is immobilized on the inner surface of the patch. (World J Nucl Med 2016, 15(4):36. ;Best Paper Award During 11th International Conference on Radiopharmaceutical Therapy Kochi, Kerala, India 13-17 Nov 2016) 5. Nanotamoxifen as a theranostic tool for breast cancer funded by PGIMER, chandigarh.Indian J Nucl Med 2016, 31 (Suppl):S10. . 8. List of Publications 1. Bhusari P, Vatsa R, Singh G, Parmar M, Bal A, Dhawan DK, Mittal BR, Shukla J. Development of Lu- 177-trastuzumab for radioimmunotherapy of HER2 expressing breast cancer and its feasibility assessment in breast cancer patients.Int J Cancer. 2016 Nov 3. doi: 10.1002/ijc.30500. [Epub ahead of print] (Corresponding Author). 2. Vadi SK, Chouhan DK, Gorla AKR, Shukla J, Sood A, Mittal BR. Potential Adjunctive Role of Radiosynovectomy in Primary Synovial Osteochondromatosis of the Knee: A Case Report. Nucl Med Mol Imaging. DOI: 10.1007/s13139-016-0466-1 3. Sood A, Sharma A, Chouhan DK, Gupta K, Parghane R, Shukla J, Mittal BR. Failed Radiation Synovectomy in Diseased Knee Joint with Missed Tuberculous Synovitis. World J Nucl Med. 2016 Sep;15(3):206-8. doi: 10.4103/1450-1147.167606 4. Jain TK, Basher RK, Shukla J, Bhattacharya A, Prakash M, Mittal BR. Ga-68 DOTA-NOC PET/CT for the detection of residual/recurrence in a rare case of sacral spinal canal paraganglioma. World J Nucl Med 2016;15:71-2. (letter to editor). 5. Jain TK, Basher RK, Gupta N, Shukla J, Singh SK, Mittal BR. Unusual Presentation of Bladder Paraganglioma: Comparison of (131)I MIBG SPECT/CT and (68)Ga DOTANOC PET/CT. World J Nucl Med. 2016 Jan-Apr;15(1):65-7. doi: 10.4103/1450-1147.167591. 6. Jain TK, Basher RK, Shukla J, Mittal BR, Panda NK. Malignant Jugular Paraganglioma: Unusual Presentation on 68Ga DOTANOC PET/CT.ClinNucl Med. 2016 Feb;41(2):150-2. doi: 10.1097/RLU.0000000000001077. 7. Jung RS, Mittal BR, Maturu VN, Agarwal R, Bal A, Dey P, Shukla J, Gupta D. 18F-FDG and 18F-FLT PET/CT imaging in the characterization of mediastinal lymph nodes. Ann Nucl Med 2015. DOI: 10.1007/s12149-015-1047-6. 8. Shukla J, Dinda AK, Srivastava AK, Srivastava K, Mittal BR, Bandopadhyaya GP. Nanotamoxifen delivery system: Toxicity assessment after oral administration and biodistribution study after intravenous delivery of radiolabeled nanotamoxifen. World J Nucl Med 2016;15:7-11. 9. Shukla J, Mittal BR. Dimercaptosuccinicacid:A multifunctional cost effective agent for imaging and therapy. Indian J Nucl Med 2015;30:295-302. (Corresponding Author) 10. Arora G, Dubey P, Shukla J, Ghosh S, Bandopadhyaya G. Evaluation of cytotoxic and tumor targeting capability of (177)Lu-DOTATATE-nanoparticles: a trailblazing strategy in peptide receptor radionuclide therapy. Ann Nucl Med. 2016 Jun;30(5):334-45. doi: 10.1007/s12149-016-1067-x. 11. Chakravarty R, Chakraborty S, Ram R, Vatsa R, Bhusari P, Shukla J, Mittal BR, Dash A. Detailed evaluation of different (68)Ge/(68)Ga generators: an attempt toward achieving efficient (68)Ga radiopharmacy. J Labelled Comp Radiopharm. 2016 Mar;59(3):87-94. doi: 10.1002/jlcr.3371. 12. Shukla J, Mittal BR. Dimercaptosuccinic acid: A multifunctional cost effective agent for imaging and therapy. Indian J Nucl Med. 2015;30(4):295-302. (Corresponding Author) 13. Rayamajhi SJ, Mittal BR, Shukla J, Vatsa R, Bhattacharya A, Mandal AK. Recurrent Urinary Bladder Paraganglioma Detected on 68Ga DOTANOC PET/CT.ClinNucl Med. 2015 Oct;40(10):e490-1. doi: 10.1097/RLU.0000000000000910. 14. Bhusari P, Vatsa R, Singh G, Dhawan DK, Shukla J, Mittal BR. Development and characterization of DTPA-Trastuzumab conjugates for radiolabeling with Tc-99m: a radiopharmaceutical for HER2/neu breast cancer. J Drug Delivery Sci Technol.2015; 29:8-15.(Corresponding Author). 15. Vatsa R, Bhusari P, Kumar S, Chakraborty S, Dash A, Singh G, Dhawan DK, Shukla J, Mittal BR. Integrin αvβ3 as a Promising Target to Image Neoangiogenesis Using In-House Generator-Produced Positron Emitter 68Ga-Labeled DOTA-Arginine-Glycine-Aspartic Acid (RGD) Ligand. Cancer BiotherRadiopharm. 2015;30(5):217-224. (Corresponding Author) 16. Agrawal K, Bhadada S, Mittal BR, Shukla J, Sood A, Bhattacharya A, Bhansali A. Comparison of 18F- FDG and 68Ga DOTATATE PET/CT in Localization of Tumor Causing Oncogenic Osteomalacia.ClinNucl Med. 2015; 40(1): e6-e10. 17. Jung RS, Mittal BR, Bal A, Dey P, Shukla J, Kapoor R. Metastatic Melanoma to the Thyroid Gland Expressing Somatostatin Receptors-Imaging With 68Ga-DOTANOC PET/CT.ClinNucl Med. 2015;40(2):175-6. 18. Parghane RV, Basher RK, Vatsa R, Shukla J, Bhattacharya A, Mittal BR. Breast Metastasis Detected on Ga-68 DOTATATE Positron Emission Tomography/ Computed Tomography Imaging in Malignant Pheochromocytoma.World J Nucl Med. 2015; 14(1): 69-70. 19. Parghane RV, Mittal BR, Shukla J, Dey P, Bhattacharya A, Kochhar R. Paraganglioma and Pancreatic Neuroendocrine Tumor With Rare Metastatic Sites Detected on 68Ga-DOTATATE PET/CT Imaging.ClinNucl Med. 2015; 40(3): 256-7. 20. Biswal CK, Mittal BR, Shukla J, Vatsa R, Bhattacharya A, Prabhakar S. Fluorothymidine PET/CT in Neurolymphomatosis. ClinNucl Med 12/2014; 40(5). DOI:10.1097/RLU.0000000000000632. 21. Parghane RV, Agrawal K, Mittal BR, Shukla J, Bhattacharya A, Gupta A. 68Ga DOTATATE PET/CT Imaging of a Solitary Fibrous Tumor of the Nasopharynx. ClinNucl Med.2014; 39(8):e382-3. 22. Agrawal K, Kumar R, Shukla J, Bhattacharya A, Mittal BR. Ga‑68 DOTATATE positron emission tomography/computer tomography in initial staging and therapy response evaluation in a rare case of primary neuroblastoma in neck. Indian J Nucl Med 2014; 29:175‑6. 23. Parghane R, Agrawal K, Shukla J, Bhattacharya A. Mittal B R. Ga-68 DOTATATE PET/CT in a rare co- existence of pituitary macroadenoma and multiple paragangliomas.ClinNucl Med,2014; 39 (1): 91-93. 24. Goel R, Shukla J, Bansal D, Sodhi K, Bhattacharya A, Marwaha RK, Mittal BR.68Ga‑DOTATATE positron emission tomography/computed tomography scan in the detection of bone metastases in pediatric neuroendocrine tumors. Indian J Nucl Med 2014;29:13‑7. (Corresponding Author) 25. Shukla J, Vatsa R, Garg N, Bhusari P, Watts A, Mittal BR. Quality control of positron emission tomography radiopharmaceuticals: An institutional experience. Indian J Nucl Med 2013;28:200‑6. (Corresponding Author) 26. Shukla Jaya, Mittal BR, Sood A, Bandopadhaya GP.CaCO3 microparticle containing ibandronate– alginate beads for improved adherence to bisphosphonate oral therapy: formulation and in-vitro release. Int J Pharm 2013, 3(2): 340-7. (Corresponding Author). 27. Sood A, Agarwal K, Shukla J, Goel R, Dhir V, Bhattacharya A, Mittal BR. Bone scintigraphic patterns in patients of tumor induced osteomalacia. Indian J Nucl Med 2013;28:173-5. 28. Arun S, Mittal BR, Shukla J, Bhattacharya A,Kumar P. Diffuse nesidioblastosis diagnosed on a Ga-68 DOTATATE positron emission tomography/computerized tomography. Indian J Nucl Med 2013;28:163-4. 29. Shukla J, Mittal BR. Ga-68: A Versatile. PET Imaging Radionuclide. J Postgrad Med Edu Res 2013;47(1):74-76. 30. Mittal BR, Agrawal K, Shukla J, Bhattacharya A, Singh B, Sood A, Bhansali A. Ga-68 DOTATATE PET/CT in Neuroendocrine Tumors: Initial Experience. J Postgrad Med Edu Res 2013;47(1):1-6. 31. Bandopadhyaya GP, Arora G, Shukla J, Ghosh S. Recognition based hormonal 95kDa monoclonal antibody on three human cancer cell lines for developing targeted radio-immuno-imaging and therapy.Hell J Nucl Med 2012; 15(2):108-13. 32. Bandopadhyaya GP, Gupta P, Singh A, Shukla J, Rastogi S, Kumar R, Malhotra A. 99mTc(V)-DMSA in Evaluation of Osteosarcoma: Comparative Studies with 18F-FDG PET/CT in Detection of Primary and Malignant Lesions. ISRN Oncol 2012; 2012: 371830. 33. Arora G, Shukla J, Ghosh S, Maulik SK, Malhotra A, Bandopadhyaya GP. PLGA Nanoparticles for Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: A Novel Approach towards Reduction of Renal Radiation Dose. PLoS One 2012; 7(3): e34019. 34. Dubey N, Shukla J, Hazari PP, Varshney R, Ganeshpurkar A, Mishra AK, Trivedi P, Bandopadhaya GP. Preparation and biological evaluation of paclitaxel loaded biodegradable PCL/PEG nanoparticles for the treatment of human neuroendocrine pancreatic tumor in mice. Hell J Nucl Med 2012; 15(1): 9- 15. 35. Dubey N, Varshney R, Shukla J, Ganeshpurkar A, Hazari PP, Bandopadhaya GP, Mishra AK, Trived P. Synthesis and evaluation of biodegradable PCL/PEG nanoparticles for neuroendocrine tumor targeted delivery of somatostatin analog. Drug Delivery 2012; 19(3):132-42. 36. Shukla J, Sharma U, Kar R, Varma IK, Juyal S, Jaganathan NR, Bandopadhyaya GP. Tamoxifen: 2- Hydroxylpropyl-Beta-Cyclodextrin Aggregated Nanoassembly for Non Breast ER-Positive Cancer Therapy. Nanomedicine 2009 4(8):,895-902. 37. Shukla J, Arora G,Kotwal PP, Kumar R, Malhotra A, Bandopadhyaya GP. Radiolabeled oligosaccharides nanoprobes for infection imaging. Hell J NuclMed 2010; 13(3):118-123. 38. Shamim SA, Kumar R, Halanaik D, Kumar A, Shandal V, Shukla J, Kumar A, Trikha V, Chandra P, Bandopadhayaya G, Malhotra A. Role of rhenium-188 tin colloid radiosynovectomy in patients with inflammatory knee joint conditions refractory to conventional therapy. Nucl Med Commun, 2010; 31:814–820. 39. Shukla J, Pandey AK, Maulik SK, Varma IK, Kumar R, Bandopadhyaya GP. Radiolabelled pentavalent Dimercaptosuccinic acid microspheres for tumor therapy: Cytotoxic assessment and biodistributionstudies.World J Nucl Med. 2008; 7(3):158-165. 40. Shukla J, Bandopadhyaya GP, Shamim SA, Kumar R. Characterization of Re-188-Sn microparticles used for synovitis treatment. Int J Pharmaceutics, 2007; 338:43-47. 41. Shukla J, Bandopadhyaya GP, Varma IK, Kumar R, Maulik SK. Morphology and release kinetics of Tc-99m(V)Dimercaptosuccinic acid loaded, PLGA microspheric delivery system. An experimental approach that may be used for targeted radiation treatment. Hell J Nucl Med 2007; 10(1): 9-13. 42. Shukla J, Bandopadhyaya GP, Varma IK. 188-Rheniume(V)Dimercaptosuccinic acid loaded PLGA microspheres for targeted radiotherapy: Production and effectivity. Die Pharmazie 2005; 60 (8): 583-585.